title: 11C-acetate PET imaging of prostate cancer.
abstract: 11C-Acetate can act as a probe of tissue metabolism through entry into catabolic or anabolic metabolic pathways as mediated by acetyl-coenzyme A. The uptake of (11)C-acetate in prostate cancer was investigated to determine whether this tracer has potential in tumor identification.
  
  
  METHODS
  Twenty-two patients with prostate cancer underwent PET after intravenous administration of 740 MBq (11)C-acetate. Eighteen of the 22 patients were also investigated with (18)F-FDG PET. Standardized uptake values (SUVs) for each tumor were investigated for tracer activity at 10-20 min after (11)C-acetate and 40-60 min after (18)F-FDG administration.
  
  
  RESULTS
  Adenocarcinoma of the prostate showed variable uptake of (11)C-acetate, with SUVs ranging from 3.27 to 9.87. In contrast, SUVs for (18)F-FDG ranged from 1.97 to 6.34. By visual inspection, (11)C-acetate accumulation in primary prostate tumors was positive in all patients, whereas (18)F-FDG accumulation was positive in only 15 of 18 patients. (11)C-Acetate PET in a patient with lymph node metastasis showed high intrapelvic accumulation corresponding to metastatic sites. Similarly, 2 patients with bone metastases were (11)C-acetate avid.
  
  
  CONCLUSIONS
  (11)C-Acetate shows marked uptake in prostate cancer and is more sensitive in detection of prostate cancer than is (18)F-FDG PET. (11)C-Acetate represents a new tracer for detection of prostate cancer with PET, measuring radiopharmaceutical uptake pathways that are different from those measured by (18)F-FDG.
authors.affiliation: Department of Urology, Fukui Medical University, Fukui, Japan. Oyaman@mir.wustl.edu
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Oyama
authors.forename: Hironobu
authors.initials: H
authors.lastname: Akino
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kanamaru
authors.forename: Yuji
authors.initials: Y
authors.lastname: Suzuki
authors.forename: Satoshi
authors.initials: S
authors.lastname: Muramoto
authors.forename: Yoshiharu
authors.initials: Y
authors.lastname: Yonekura
authors.forename: Norihiro
authors.initials: N
authors.lastname: Sadato
authors.forename: Kazutaka
authors.initials: K
authors.lastname: Yamamoto
authors.forename: Kenichiro
authors.initials: K
authors.lastname: Okada
mesh_terms: D000085:Acetates; D000230:Adenocarcinoma / Q000000981:diagnostic imaging*; D000368:Aged; D000369:Aged, 80 and over; D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary; D002244:Carbon; D002250:Carbon Radioisotopes; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008198:Lymph Nodes / Q000000981:diagnostic imaging; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging*; D019275:Radiopharmaceuticals; D012680:Sensitivity and Specificity; D014055:Tomography, Emission-Computed
chemical_list: D000085:Acetates; D002250:Carbon Radioisotopes; D019275:Radiopharmaceuticals; C438206:carbon-11 acetate; D019788:Fluorodeoxyglucose F18; D002244:Carbon